U.S. Markets close in 3 hrs 38 mins

Today’s Research Reports on Trending Tickers: Clovis Oncology and Incyte Corporation

NEW YORK, NY / ACCESSWIRE / January 12, 2017 / U.S. markets rallied sharply Thursday as investor focus has now shifted to the upcoming earnings season. The Dow Jones Industrial Average jumped 0.81 percent to close at 25,574.73, while the S&P 500 Index gained 0.70 percent to close at 2,767.56. The Nasdaq Composite Index spiked 0.81 percent to close at 7,211.78. Major financial companies, BlackRock, J.P. Morgan Chase and Wells Fargo, are on deck to report earnings on Friday. Profits of the S&P 500 are forecasted to increase by 11.8 percent in the fourth quarter, up from an 8 percent rise a year ago, according to Thomson Reuters I/B/E/S.

RDI Initiates Coverage on:

Clovis Oncology, Inc.
https://rdinvesting.com/news/?ticker=CLVS

Incyte Corporation
https://rdinvesting.com/news/?ticker=INCY

Clovis Oncology, Inc.'s stock moved 4.54% lower Thursday, to close the day at $59.93. The stock recorded a trading volume of 1,262,648 shares, which was above its three months average volume of 1,188,050 shares. In the last year, Clovis Oncology, Inc.'s shares have traded in a range of 45.42 - 99.45. The share price has gained 31.95% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $63.13 is below its 200-day moving average of $74.76. Shares of Cleveland-Cliffs have fallen roughly 4.72 percent in the past month and are down 11.87 percent year-to-date.

Access RDI's Cleveland-Cliffs Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CLVS

On Thursday, shares of Incyte Corporation recorded a trading volume of 3,251,159 shares, which was above the three months average volume of 1,634,507 shares. The stock ended the day 3.68% lower at 93.06. The stock is currently trading 39.24% below its 52 week high with a 52 week trading range of 92.52 - 153.15.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $96.69 is below its 200-day moving average of $115.24. Shares of Incyte Corporation have fallen roughly 4.31 percent in the past month and are down 1.74 percent year-to-date.

Access RDI's Incyte Corporation Research Report at:
https://rdinvesting.com/news/?ticker=INCY

Our Actionable Research on Clovis Oncology, Inc. (NASDAQ:CLVS) and Incyte Corporation (NASDAQ:INCY) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com